By Paul Ziobro
Shares of Spero Therapeutics plunged after the company said it was suspending the development of a program for a lung infection treatment and cutting 39% of jobs to preserve cash.
The stock fell 21.4% to $1.03 in late trading, after closing the regular trading session at $1.31. Through Tuesday's close, the stock had been down 10.9% this year.
The Cambridge, Mass.-based biopharmaceutical company said it would restructure after an interim analysis of a study of SPR720, a treatment for non-tuberculous mycobacterial-pulmonary disease, failed to meet its primary endpoint.
The company decided to suspend the current development program and will look at other potential paths forward as the remaining data are collected and analyzed.
Spero said the restructuring and layoffs will extend its cash runway and support operations into mid-2026.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
October 29, 2024 17:15 ET (21:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。